

Convergence

of evidence and experience in
first-line advanced ovarian cancer

*Experts debate considerations
and options for optimized
clinical management*

Saturday, 21 October 2023,
18:30-20:00 CEST
Burgos Auditorium – Hall 3
IFEMA MADRID, Madrid, Spain

*Please join your expert colleagues as they debate considerations
and options for optimized clinical management*

AGENDA



THE EVIDENCE NEXUS:

Treatment evolution in first-line
advanced ovarian cancer

Antonio González Martín, MD, PhD (Chair)
Clínica Universidad de Navarra
Madrid, Spain



NOT TOO LITTLE, NOT TOO MUCH:

What is the best 1L maintenance treatment
approach for patients with HRd tumors?

Alexandra Leary, MD, PhD
Gustave Roussy Institute of Oncology
Villejuif, France



WHAT'S NEXT:

Novel strategies to address unmet needs in
advanced ovarian cancer

Jonathan A. Ledermann, BSc, MD, FRCP, FMedSci
UCL Cancer Institute
London, United Kingdom

1L, first-line; HRd, homologous recombination deficient.

This material was developed in compliance with the EFPIA code.

©2023 GSK group of companies or its licensor. All rights reserved. NX-GBL-NRP-OGM-230009. August 2023.